This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology  • Oncology, Other  • Public Health  • Obesity  • Surgery  • Surgical Interventions  • Endocrine Surgery  • Surgical Oncology  • Prognosis/ Outcomes  • Gastroenterology  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Jason B. Fleming, MD; Ricardo J. Gonzalez, MD; Maria Q. B. Petzel, BS; E. Lin, MS; Jeffrey S. Morris, PhD; Henry Gomez, MD; Jeffrey E. Lee, MD; Christopher H. Crane, MD; Peter W. T. Pisters, MD; Douglas B. Evans, MD

Arch Surg. 2009;144(3):216-221.

Objective  To examine the influence of obesity, as measured by body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared), on clinicopathologic factors and survival after pancreatectomy to treat adenocarcinoma.

Design  Retrospective review and statistical analysis using prospectively collected data.

Setting  Referral center with a dedicated multidisciplinary pancreas cancer program.

Patients  Two hundred eighty-five consecutive patients with data available for BMI calculation who underwent potentially curative pancreas resection to treat adenocarcinoma from January 1, 1999, to October 31, 2006.

Main Outcome Measure  Influence of BMI and other known prognostic variables on the incidence of lymph node metastasis and disease-free and overall survival.

Results  We identified a subset of obese patients (BMI >35) who were at 12-fold risk of lymph node metastasis compared with nonobese patients (BMI 35). The estimated disease-free and overall survival rates were decreased in the obese patients, and the risk of cancer recurrence and death after pancreatectomy was nearly twice that in nonobese patients.

Conclusions  Obese patients with a BMI of more than 35 are more likely to have node-positive pancreatic cancer and decreased survival after surgical resection. Data suggest that the negative influence of BMI of more than 35 on cancer-related end points is unrelated to the potential complexity of performing major oncologic surgery in obese patients.

Author Affiliations: Departments of Surgical Oncology (Drs Fleming, Gomez, Lee, Pisters, and Evans), Clinical Nutrition (Ms Petzel), Biostatistics (Ms Lin and Dr Morris), and Radiation Oncology (Dr Crane), The University of Texas M. D. Anderson Cancer Center, Houston; and the Department of Surgery, University of Colorado at Denver and Health Sciences Center, Denver (Dr Gonzalez).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Body Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer
Li et al.
JAMA 2009;301:2553-2562.
ABSTRACT | FULL TEXT